Photodynamic therapy of cervical intraepithelial neoplasia grades II and III with Photolon.
The objective of the present study was to test in clinics a previously developed novel organ-saving approach for the treatment of CIN using PDT with the photosensitizer Photolon applied in women of a childbearing age with CIN II and III. A total number of 112 patients aged 35.2+/-1.6 with morphologically proven diagnosis of CIN II and III were enrolled into the study. All 112 patients had been observed at least during 1-year follow-up period after PDT. Among them 53 patients (44.1%) were subjected to a dynamic observation for less than 2 years; 29 patients (24.1%) were under the observation for less than 3 years; 13 patients (10.8%) - for 3-4 years and 17 women - for more than 4 years. A complete response represented by the complete regression of neoplastic lesions, which was proved by the results of morphological examinations, was revealed in 104 (92.8%) of treated women. In 3 months after treatment a complete eradication of the HPV infection was proven by PCR-analysis in 47 (53.4%) from 88 patients who have been infected with HPV of a highly oncogenic strains before PDT. PDT with Photolon is an alternative approach for the treatment of cervical intraepithelial neoplasia which can be recommended for women of childbearing age. The simplicity of the procedure as well as its' high therapeutic efficacy defines the reasonability of its' introduction into the clinical practice as a new organ-saving method for the treatment of patients with cervical intraepithelial neoplasia.
Istomin
Y P
YP
National Cancer Center Republic of Belarus, Lesnoy-2, Minsks' area, 223040 Belarus. istomin06@mail.ru
Lapzevich
T P
TP
Chalau
V N
VN
Shliakhtsin
S V
SV
Trukhachova
T V
TV
D000328:Adult; D002735:Chlorophyllides; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D030361:Papillomavirus Infections / Q000150:complications / Q000188:drug therapy; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins; D011205:Povidone / Q000627:therapeutic use*; D011524:Protoporphyrins / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D002735:Chlorophyllides; D017319:Photosensitizing Agents; D011166:Porphyrins; D011524:Protoporphyrins; C062985:phytochlorin; D011205:Povidone